Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue - PubMed

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue - PubMed

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue

Yankui Liu 1, Longhai Li 2, Yu Tian 2, Xiao Zhu 3, Aijuan Sun 4, Yulong Sun 4, Yan Qiao 4, Xiaowei Qi 1, Tao Wang 4

Affiliations 

• PMID: 32876508
 
• DOI: 10.1080/10520295.2020.1810775

Abstract

The mutation status of KRAS is important for anti-EGFR therapy in colorectal cancer (CRC) patients; however, detection of KRAS mutations in circulating tumor DNA (ctDNA) is problematic. We investigated tissue and plasma assays for KRAS mutations in CRC patients. The KRAS status of 407 CRC patients was evaluated using integration of amplification refractory mutation system polymerase chain reaction (PCR), melting curves and wild type DNA blocking (IAMB) in tissue and plasma samples. Disparate cases were re-evaluated by Sanger sequencing of tissue samples. General characteristics and tumor biomarkers including CEA, CA19-9 and CA125 were characterized. The prevalence of KRAS mutations was 40.8% in plasma and 49.1% in tissue. The overall percent agreement, positive percent agreement and negative percent agreement were 82.3, 76.3 and 90.8%, respectively. Older patients and higher TNM stage exhibited increased sensitivity for detecting KRAS mutations in plasma. We found 54.1% of patients with KRAS mutations using parallel analysis of tissue and plasma; only 36.4% of patients were detected by series analysis. We found that plasma based KRAS detection with IAMB technology is an alternative to tissue based KRAS testing. KRAS mutations can be identified more easily when both assays are used together.

Keywords: KRAS; Anti-EGFR MoAbs; DNA; colorectal cancer; human; mutation; tumor.

Similar articles

• Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.

  Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S.Ann Oncol. 2015 Apr;26(4):731-736. doi: 10.1093/annonc/mdv005. Epub 2015 Jan 26.PMID: 25628445 Free PMC article.
• Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

  Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.PMID: 26184520
• Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.

  Gao J, Wu H, Wang L, Zhang H, Duan H, Lu J, Liang Z.BMJ Open. 2016 Jan 8;6(1):e009532. doi: 10.1136/bmjopen-2015-009532.PMID: 26747035 Free PMC article.
• Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

  Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.PMID: 23429431
• Circulating Tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor - a systematic review and meta-analysis.

  Perdyan A, Spychalski P, Kacperczyk J, Rostkowska O, Kobiela J.Crit Rev Oncol Hematol. 2020 Aug 1;154:103065. doi: 10.1016/j.critrevonc.2020.103065. Online ahead of print.PMID: 32763752 Review.